mAbxience, a Fresenius Kabi majority-owned group, and Egis have entered a strategic commercialization agreement for two biosimilar candidates in key Central and Eastern European markets. Fresenius Kabi, an operating company of Fresenius, continues to reinforce its biopharma business and strategic network through this new agreement with Egis. This directly underscores the mutual commitment of both companies to broadening access to essential, high-quality biosimilar therapies in markets where affordability and accessibility are critical. The agreement strengthens Fresenius Kabi’s presence in Central and Eastern Europe and reaffirms its dedication to drive innovation and accessibility of life-saving treatments in global healthcare, all in line with #FutureFresenius.

Fresenius, via its operating company Fresenius Kabi, and Cellular Origins, a TTP Company, have entered an agreement to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation™ automation platform. The agreement aims to leverage each company’s expertise in cell and gene therapies (CGTs) for digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation™. Initial focus will be on integration of the Cue® Cell Processing System for automated small volume processing. Driving innovation by building momentum in cell and gene therapy, is a further milestone of #FutureFresenius.

mAbxience, a Fresenius Kabi majority-owned group, and Teva Pharmaceuticals International have entered a second global licensing agreement for an anti PD-1 biosimilar candidate currently in development for the treatment of multiple oncology indications. The agreement covers global markets, including in Europe and the United States. Fresenius Kabi, an operating company of Fresenius, continues to strengthen its biopharma business and strategic network through this new agreement, which builds on the solid foundation of the initial partnership with Teva. This directly underscores the companies’ mutual goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging expertise and resources, the collaboration continues to drive innovation and accessibility in global healthcare, all in line with #FutureFresenius.

The healthcare group Fresenius has achieved a further milestone in the implementation of #FutureFresenius with the successful completion of the divestment of Vamed’s rehabilitation business to the international private equity firm PAI Partners. Fresenius retains a minority stake of 30 percent in the business. The transaction, which was announced in May 2024, has received all necessary regulatory approvals and the closing conditions have been met. The rehabilitation business which also includes specialized healthcare services in the areas of prevention, acute care and nursing, was Vamed's largest business unit. With approximately 13,000 employees, it provides inpatient and outpatient rehabilitation services to approximately 100,000 patients every year in various European countries.

After having received the European Commission approval just recently, Fresenius, via its operating company Fresenius Kabi, and its license partner Formycon announced that the United States (U.S.) Food and Drug Administration (FDA) has approved OtulfiTM (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara®** (ustekinumab). OtulfiTM is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. In accordance with the patent settlement between Formycon, Fresenius Kabi and Johnson & Johnson, Fresenius Kabi has the right to market OtulfiTM in the U.S. no later than February 22, 2025. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma business, which is a substantial cornerstone of #FutureFresenius. * OtulfiTM (ustekinumab-aauz) is a trademark of Fresenius Kabi Deutschland GmbH in selected countries ** Stelara® is a registered trademark of Johnson & Johnson

Fresenius, via its operating company Fresenius Kabi, and its license partner Formycon announced that the European Commission (EC) granted marketing authorization for FYB202, a biosimilar candidate to Stelara® (ustekinumab) indicated for the treatment of several serious inflammatory diseases. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. In March 2024, Formycon and Fresenius Kabi reached a settlement agreement with Johnson & Johnson concerning the commercialization of their ustekinumab biosimilar in Europe and Canada. The terms of the agreement are confidential. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma business, which is a substantial cornerstone of #FutureFresenius. Stelara® is a registered trademark of Johnson & Johnson

The rate of change, a key parameter for determining the price increase for the reimbursement of hospital treatments in 2025 in Germany, has been set at 4.41%. The change in hospital costs is the other parameter used in the annual determination of the reimbursement increase. The final DRG inflator should be determined at the latest by the end of the year.

Fresenius continues streamlining the production network of its Operating Company Fresenius Kabi in line with its Vision 2026 and #FutureFresenius: Today, Fresenius Kabi transferred the ownership of its subsidiary Laboratorio Sanderson S.A., Chile, to Medifarma, a multinational pharmaceutical company from Peru with a strong presence in Latin America. This divestment includes the IV Laboratorio Sanderson plant in Santiago de Chile. Medifarma will continue the manufacturing of the existing portfolio of products in Chile. Fresenius Kabi remains committed to the Chilean as well as South American markets and will continue its presence accordingly. This is another step to reduce complexity and optimize utilization in Fresenius Kabi’s global manufacturing network.

Fresenius Kabi today announced the launch of Cetrorelix Acetate for Injection Kit, an FDA-approved, cost-effective, generic option for women’s health. Cetrorelix Acetate for Injection is a therapeutic equivalent to EMD Serono’s Cetrotide®. With this new generic, Fresenius Kabi underscores its commitment to providing a comprehensive range of cost-effective treatment options in the field of women’s health, helping to support their options in the U.S. For more information, please see the website of Fresenius Kabi.

Fresenius, via its operating company Fresenius Kabi, and its license partner Formycon announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for the marketing authorization of FYB202, a biosimilar candidate to Stelara® (ustekinumab) indicated for the treatment of several serious inflammatory diseases. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. The positive CHMP opinion is the latest development in Fresenius Kabi’s continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio. Growing the company's (Bio)Pharma platform is a substantial cornerstone of #FutureFresenius. Stelara® is a registered trademark of Johnson & Johnson

Fresenius, via its operating company Fresenius Kabi, announced that the European Medicines Agency (EMA) has accepted for review the company’s Marketing Authorization Applications (MAAs) for its biosimilar candidates of Prolia® (denosumab) and Xgeva® (denosumab). The two applications include all indications covered by the reference products, respectively, for treating different conditions including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that have spread to the bone, and giant cell tumor of the bone.1,2 The EMA Marketing Authorization Applications’ acceptance is the latest development in Fresenius Kabi’s continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio. Growing the company's Biopharma platform is a substantial cornerstone of #FutureFresenius. Prolia® and Xgeva® are registered trademarks of Amgen Inc.

Fresenius, via its operating company Fresenius Kabi, announced today the immediate availability of its biosimilar Tyenne® (tocilizumab-aazg) in a subcutaneous formulation in the U.S, continuing its (Bio)Pharma momentum. With this launch Fresenius is increasing access to affordable and cost-effective treatment options for use in the treatment of chronic autoimmune diseases. This is another important milestone in accelerating the company’s strong (Bio)Pharma momentum, a substantial cornerstone of #FutureFresenius. Tyenne®, the company’s third biosimilar in the U.S., was launched in an intravenous (IV) formulation in April this year.

Fresenius published its first Sustainability Highlights Report today. In the online report, the company presents its sustainability strategy, ambitions and highlights. In addition, the company reports on Scope 3 emissions for the first time, thereby creating full transparency across the entire value chain.

The rating agency S&P Global Ratings today revised the credit outlook for Fresenius SE from negative to stable. The rating was affirmed at BBB. In particular, S&P acknowledged Fresenius's improved operating performance, its simplified structure and capacity to deliver on its profitable growth plans. "The revised outlook is further proof that #FutureFresenius is paying off. It confirms our focus on profitable growth, liquidity, and capital efficiency. Based on the operational strength of our operating companies Fresenius Kabi and Fresenius Helios, we expect to be within our self-imposed leverage target corridor by year end," said Fresenius CFO Sara Hennicken. Fresenius is rated investment grade by the three leading rating agencies S&P Global Ratings (BBB/stable), Moody's (Baa3/stable) and Fitch (BBB-/stable). The company expects that it will be within its self-imposed leverage corridor of 3.0 to 3.5x net debt/EBITDA by the end of 2024.